Integrins are a family of transmembrane glycoproteins playing important roles in tumor invasion, metastasis, and neovascularization by mediating cell-extracellular matrix (ECM) interaction and initiating intracellular signaling. 1, 2) Integrin consists of 2 noncovalently associated subunits (a and b), and currently 18 a and 8 b subunits have been identified in humans, which are able to form 24 distinct integrin heterodimers.
Integrin consists of 2 noncovalently associated subunits (a and b), and currently 18 a and 8 b subunits have been identified in humans, which are able to form 24 distinct integrin heterodimers. 3) Many integrins are known to recognize the tripeptide sequence Arg-Gly-Asp (RGD), which has been found in a wide variety of ECM proteins such as fibronectin (FN), vitronectin (VN), osteopontin, thrombospondin, fibrinogen, von Willebrand factor, collagens and laminin. 4, 5) Recognition and binding between integrin receptor and RGD ligand may depend on intrinsic integrin affinity (via conformational changes) and spatial distribution of the ligands, which can be regulated by microenvironmental divalent cations and RGD-neighbouring sequence, respectively. 6, 7) Various RGD-containing peptides have been increasingly developed for adapting to versatile applications including tumor imaging and therapy, drug delivery vector, targeted gene transfer, and biomaterial or tissue engineering. 3, [8] [9] [10] [11] FN is a very important RGD-containing ECM protein, involved in malignant progression and metastasis, and used as a target for tumor therapy. [12] [13] [14] FN has been found to serve as a ligand for many integrins including a 3 b 1 , a 5 b 1 , a 8 b 1 , a V b 1 , a V b 3 , a V b 5 , a V b 6 and a IIb b 3 via its RGD motif. 15) Multivalent interactions are frequently used in nature to increase the affinity of weak ligand-receptor interactions, 16, 17) and multimerization has become a principal strategy for the development of cyclic RGD peptides (cRGD) for targeting integrin a V b 3 . 18) This protein is highly expressed on activated endothelial cells during angiogenesis, 19, 20) a requirement for tumor growth and metastasis, and also frequently overexpressed on many types of tumor cells. 2, 21) Its overexpression has been known to correlate well with tumor progression, invasion and metastasis. 2, 22) In this study, we evaluated the effect of multimerization of a linear RGD peptide, Ala-ValThr-Gly-Arg-Gly-Asp-Ser-Tyr (AVTGRGDSY), on the binding affinity and specificity of integrin a V b 3 or b 1 , a subunit that forms complexes with various a integrin subunits, using a V b 3 -positive cells and a V b 3 -negative/b 1 -overexpressing cells. AVTGRGDSY was derived from the amino acid sequence AVTGRGDSP in FN, with "P" being replaced by the tyrosine residue "Y" for 125 I-labeling. Here we describe the synthesis of mono-, di-and trimeric AVTGRGDSY peptides, the radio-or fluorescence dye-labeling of these peptides, and evaluation of their biological characteristics both in vitro and in vivo.
MATERIALS AND METHODS

Synthesis of AVTGRGDSY Peptides
Monomeric AVT-GRGDSY peptide (RGD-monomer) was synthesized using peptide synthesizer by standard 9-fluorenylmethoxycarbonyl (Fmoc) method. The monomer was dissolved in dimethyl sulfoxide (DMSO) and pH was adjusted to 9 with triethylamine. Cross-linking reactions were performed using disuccinimidyl glutarate (DSG) for obtaining a dimeric-AVT-GRGDSY (RGD-dimer) and tris-succinimidyl aminotriacetate (TSAT) for a trimeric AVTGRGDSY (RGD-trimer). DSG and TSAT were purchased from Pierce (Rockford, IL, U.S.A.), and the monomer was reacted with 1/2 molar ratio of DSG or with 1/3 molar ratio of TSAT for 16 h at room temperature (RT). The products were purified with HPLC and freeze-dried. Mass analysis showed the results: RGDmonomer (Fig. 1A) Synthesis of Cy5.5-AVTGRGDSY Peptides RGDmonomer-resin was synthesized using peptide synthesizer by standard Fmoc method. Boc-Glu-COOH (0.025 mmol) (Boc: t-Butoxycarbonyl) in 0.1 mmol HBTU/HOBT solution (HBTU: 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium Hexafluorophosphate; HOBT: 1-Hydroxybenzotriazole) was incubated with four equivalents of RGD-monomer in 0.1 mmol HBTU/HOBT solution for 16 h to obtain an amino-containing RGD-dimer (Glu(AVTGRGDSY)-AVT-GRGDSY). This was followed by cleavage of peptide from resin with TFA (trifluoroacetic acid) cocktail solution (125 ml TFA, 0.25 ml H 2 O, 0.375 g phenol, 0.125 ml ethanedithiol and 0.25 ml thioanisole). The crude product was purified by RP (reversed phase)-HPLC. RGD-monomer and amino-containing RGD-dimer were conjugated with 1 mg Cy5.5 mono NHS (N-hydroxysuccinimide) ester (GE Healthcare UK Ltd., Buckinghamshire, U.K.), respectively, per manufacturer's instructions. Briefly, 1 mg peptide in 400 ml DMSO was added to two equivalents of Cy5.5 in 100 ml DMSO and incubated for 16 h to yield Cy5.5-labeled peptide that was purified with RP-HPLC and freeze-dried. Mass analysis showed the results: Cy5.5-RGD-monomer (Fig. 1A) 23) All cell lines were cultured at 37°C in a humidified 95% air/5% CO 2 atmosphere.
125
I-Radiolabeling RGD-monomer, -dimer and -trimer were labeled with iodine-125 ( 125 I) using the chloramine-T method. 25) The peptide (4.55 ml, 4.55ϫ10 -11 mole) was added to a 1.5 ml tube containing 23.45 ml of phosphate buffer (0.3 M PB, pH 7.5). One ml of Na 125 I (3.7 GBq/ml, 4.55ϫ 10 Ϫ11 mole, PerkinElmer Japan Co., Ltd., Yokohama, Japan) (peptide : 125 Iϭ1 : 1 molar ratio) was added to the tube, followed by 1 ml of the oxidant chloramine-T (2 mg/ml in H 2 O). In addition, 1 : 2 and 1 : 3 peptide :
I molar ratios were also tested for labeling of dimer and trimer, respectively. The reaction mixture was gently mixed and incubated at RT for 5 min, and radioiodination was then stopped by addition of The RGD-monomer was labeled with 125 5 ml of reductant, Na 2 S 2 O 5 (1 mM in H 2 O). An aliquot (1 ml) of the mixture was retained for counting the radioactivity employed, and the rest was used for purification by size exclusion chromatography using Sephadex G-15 media (GE Healthcare Bio-Sciences, Uppsala, Sweden) packed into a glass Econo-Column column (0.7ϫ15 cm, 6 ml, Bio-Rad Laboratories Inc., Hercules, CA, U.S.A.) with phosphatebuffered saline (PBS, pH 7.4) as elution buffer. Fractions (160 ml/fraction) were automatically collected, and 1-ml aliquots from each fraction were counted for radioactivity. An elution profile of radioactivity against the fraction number was plotted (Fig. 1B) , and the fractions containing radioiodinated peptide were identified, pooled and stored at 4°C for experiments. Throughout the present study, radioactivity (cpm) was measured using an auto-well g-counter (Aloka ARC370M, Tokyo, Japan).
Cell-Binding Assay Binding assay was performed in a similar manner as described in the literature. 26) In brief, cells were harvested with trypsin/ethylenediaminetetraacetic acid (EDTA), rinsed with Hank's Balanced Salt Solution (HBSS), and resuspended in binding buffer (HBSS, 25 mM N-(2-hydroxyethyl)piperazine-NЈ-2-ethanesulfonic acid (HEPES), 0.1% bovine serum albumin (BSA)) containing divalent cations as indicated. Each 1 ml of cell suspension (2.5ϫ10 6 cells) was then transferred into 1.5 ml tubes, followed by addition of 125 I-labeled RGD-monomer, -dimer or -trimer (60000 cpm/10 ml), and incubated for 1 h on ice. After rinsing with ice-cold PBS, the supernatant was aspirated and the radioactivity bound to cells was counted. The purpose of using low temperature is to keep cells in a low metabolic state for minimizing endocytosis and exocytosis. The relative cell-binding ratio was defined as the % of cell-bound radioactivity to the total radioactivity added.
For competitive inhibition assays, the radioactivity bound to cells was measured after co-incubation of radiolabeled RGD peptides with increasing concentrations of unlabeled corresponding peptides or cyclo(RGDfV) (c(RGDfV), a highly effective a V b 3 antagonist (Peptide Institute, Inc., Osaka, Japan)).
Cell Adhesion Assay The InnoCyte TM Cell Adhesion Microplate Assay Kit (EMD Biosciences Inc., La Jolla, CA, U.S.A.) was used for determining the inhibitory effects of RGD-monomer, -dimer and -trimer as well as c(RGDfV) on HEK293(b 3 ) cell attachment to FN or VN. The assay was performed according to the manufacturer's instructions. In brief, HEK293(b 3 ) cells were harvested and resuspended in binding buffer containing 1 mM Mn 2ϩ at a density of 500000 cells/ml. The cell suspension was incubated with these peptides (1.6 mM), respectively, for 20 min at 37°C, and then each 100 ml of the reaction mixture was added to the FN-or VN-coated 96-well plates and incubated for 1 h at 37°C. After removal of the binding buffer and gentle washing with PBS, fluorescent dye calcein-AM solution was added and incubated for 1 h at 37°C. The relative cell attachment was determined by measuring the fluorescence of the samples by microplate reader at excitation wavelength of 485 nm and emission wavelength of 520 nm.
Confocal Microscopy HEK293(b 1 ) and HEK293(b 3 ) cells were grown on Lab-Tek TM chambered coverglass (Nunc Thermo Fisher Scientific, Roskilde, Denmark). The culture medium was replaced with ice-cold binding buffer, and the cells were incubated for 1 h at 4°C with 1 mM Cy5.5-RGDmonomer or -dimer in the absence of divalent cation (HEK293(b 1 )) or presence of Mn 2ϩ or Ca 2ϩ /Mg 2ϩ (1 mM for each cation) (HEK293(b 3 )). Afterwards, the cells were rinsed with ice-cold PBS and observed by Olympus Fluoview TM FV1000 confocal laser scanning microscopy. Cy5.5 fluorescence was detected using an UPlanSApo 20ϫ objective lens and HeNe (R) (633 nm) excitation and a variable barrier filter set for Cy5.5 acquisition. Brightfield images were simultaneously acquired.
In Vivo Fluorescence Imaging Animal procedures were approved by the pertinent committee of our institution and performed in compliance with national and institutional rules for the conduct of animal experimentation. Tumor xenografts were established by subcutaneous (s.c.) injection of 10ϫ10 6 HEK293(b 1 ) or HEK293(b 3 ) cells into the right flank of the female athymic nude mice (BALB/cA Jcl-nu/nu, CLEA Japan, Inc.). When approximate 10 mm-diameter tumors developed, the mice were used for fluorescence imaging study by receiving intravenous (i.v.) injection of 10 nmol Cy5.5-RGD-monomer, -dimer or Cy5.5 alone. Imaging was performed using the Maestro TM In-Vivo Imaging System (CRi Inc., Woburn, MA, U.S.A.) with a red excitation filter (615 to 665 nm) and a 700 nm long-pass emission filter. A tunable filter was automatically stepped in 10-nm increments from 680 to 950 nm with the same exposure time of 100 ms for images captured at each wavelength.
Statistical Analysis Results are shown as meanϮstan-dard deviation (S.D.) for each index, respectively. Significant levels were calculated by ANOVA and multiple comparisons (Dunnett's test). Values of pϽ0.05 were considered significant.
RESULTS
Radiolabeling of Peptides with
125
I When 1 : 1 of peptide : 125 I molar ratio was used, the yield of radioiodination reaction for RGD-monomer, -dimer and -trimer was 80-90%, and the specific radioactivity was around 80, 37 and 23 MBq/mg, respectively. The ratios 1 : 2 and 1 : 3 resulted in decreased labeling yield for dimer (67%) and trimer (56%), respectively. Hence, all the labeling was performed at the ratio of 1 : 1 for the following studies. The purified 125 I-peptides were kept at 4°C, with the addition of BSA at final 0.1% for preventing the labeled peptides from adhering to the container surface. Gel filtration analysis confirmed that no significant radiolysis occurred within one week of storage.
In Vitro Cell-Binding Studies The cell-binding activities of 60000 cpm of 125 I-labeled RGD-monomer, -dimer and -trimer, at final concentrations of about 2.4ϫ, 2.6ϫ, and 2.9ϫ10 Ϫ11 M respectively, were assessed and compared using HEK293, HEK293(b 1 ), HEK293(b 3 ) and U87MG cells (Fig.  2) . All of the peptides showed negligible binding to HEK293 cells in the presence of Ca 2ϩ /Mg 2ϩ or Mn 2ϩ ( Fig. 2A) . When HEK293(b 1 ) cells were used (Fig. 2B) , the RGD-monomer exhibited relatively high binding activity in the presence of either Ca , and further substantial increase was observed with the RGD-dimer and -trimer (Fig. 2C) . Improved cell binding by multimerization was also observed in U87MG cells (Fig.  2D) . No marked difference in cell-binding activity between the RGD-dimer and RGD-trimer was observed. We also examined the cellular binding of Different radioactivity doses of 125 I-labeled RGDmonomer, -dimer or -trimer (ranging from 10000 to 60000 cpm) were also compared and not found to lead to a significant difference in the cell-binding ratios (data not shown). For example, the binding ratios of 125 I-labeled RGDdimer to HEK293(b 3 ) cells were 80%Ϯ2.9%, 86%Ϯ5.4% and 83%Ϯ5.1% at 10000, 30000, and 60000 cpm, respectively.
The cell-binding specificity of 125 I-labeled RGD-monomer, -dimer and -trimer was evaluated by competitive inhibition assay using the unlabeled counterparts as well as a V b 3 -specific c(RGDfV) (Fig. 3) . The binding of 125 I-RGD-monomer to HEK293(b 1 ) cells (Fig. 3A) was inhibited by the unlabeled RGD-monomer in a dose-dependent manner, with Ͼ90% inhibition achieved at 10 mM and nearly 99% inhibition at 100 mM. No inhibition was seen with c(RGDfV). Similar results with the RGD-monomer were observed in HEK293(b 3 ) cells except that c(RGDfV) showed a blocking effect with a maximal 40% inhibition at 0.1 mM (Fig. 3B) , with no stronger blocking at higher concentrations. The binding of 125 I-RGD-dimer to HEK293(b 3 ) cells was dosedependent and almost identically inhibited by both the unlabeled RGD-dimer and c(RGDfV), with around 99% inhibition at 1 mM (Fig. 3C) . Similar results were obtained for the 125 I-RGD-trimer (Fig. 3D) .
Effects of AVTGRGDSY Peptides on Cell Adhesion to FN or VN
The effect of RGD-monomer, -dimer and -trimer on a V b 3 -positive HEK293(b 3 ) cell adhesion to FN or VN was examined and compared with the reference c(RGDfV) (Fig. 4) . Both FN and VN are known as natural ligands for a V b 3 integrin, 5) but their a V b 3 -positive cell adhesion ability could be differently influenced by cRGD-containing peptides. 27) For FN (Fig. 4A) , none of the peptides showed a significant effect on cell attachment. For VN (Fig.  4B) , the RGD-monomer showed a low but significant inhibitory effect, whereas the RGD-dimer and RGD-trimer were nearly as effective as c(RGDfV) in significantly inhibiting cell attachment when same molar concentration was used.
Confocal Microscopic Observation of Cy5.5-RGD Peptide Conjugate Distribution We examined the binding and subcellular localization of Cy5.5-RGD-monomer and Cy5.5-RGD-dimer by observing the fluorescence of cells after incubation with them (Fig. 5) . It might be necessary to mention that the present microscopy study used cells cultured in wells without specific coating for visualizing the binding of RGD peptide to ligand-unoccupied integrins to avoid confusion with the result shown in Fig. 4B that RGDdimer and -trimer strongly blocked cell adhesion to VN- (Fig. 5B) or Cy5.5-RGDdimer (Fig. 5D) , with the latter producing stronger fluorescence than the former. In addition, while most of the Cy5.5 signal was found on the cell membrane, intracellular signal was also easily visualized in Cy5.5-RGD-dimer-treated cells (Fig. 5D, a-c) .
In Vivo Fluorescence Imaging Nude mice bearing s.c. tumor xenografts of HEK293(b 1 ) or HEK293(b 3 ) cell line received an i.v. injection of 10 nmol Cy5.5-RGD-monomer, Cy5.5-RGD-dimer, or Cy5.5 alone and were imaged at different time points during 24 h. As expected, Cy5.5 alone was not retained in the tumor at any time point observed, whereas Cy5.5-RGD conjugates generally could produce better tumor contrast as soon as 2 h postinjection. Figure 6 shows representative monochrome images collected at 720 nm (the peak emission wavelength for the 2 Cy5.5-RGD conjugates in mice) at 3 h. It was shown that Cy5. contrast, Cy5.5-RGD-dimer accumulated in a V b 3 -positive HEK293(b 3 ) tumor, but not in the a V b 3 -negative HEK293(b 1 ) tumor, demonstrating its specificity for a V b 3 . In addition, the obvious kidney uptake of Cy5.5-RGD-dimer may reflect the prominent renal excretion of this probe.
DISCUSSION
The effect of the multivalency for RGD-based peptides has been reported in literature by a number of groups as reviewed by Vives et al. 18) Cyclic RGD structures are proved highly specific for a V b 3 integrin receptor, 28) and multimerization can lead to increased binding affinity for the receptor. 23, 24, 27, [29] [30] [31] [32] [33] On the other hand, linear RGD peptides may interact with several integrins, including a V b 3 and b 1 integrins. [34] [35] [36] [37] Although the multivalent effects were also reported for the linear RGD, [38] [39] [40] less information was put forward concerning an effect on the integrin specificity. In this This result also suggests the functional integrity of our linear RGD peptides with a V b 3 integrin. FN is a ligand for a V b 3 , but also a ligand for several other integrin receptors. 5, 15) That is possibly why blocking a V b 3 by pre-incubation with these peptides was not sufficient to influence cell adhesion to FN. Li et al. reported similar results using cRGD-containing peptides against VN versus FN. 27) It is thus demonstrated that the RGD-dimer and -trimer exhibit, compared to the monomer, more specificity to a V b 3 integrin. This is the most important point since it points out that adding one more AVTGRGDSY sequence to the monomer greatly influences the binding mode. The binding site of dimer and trimer shares with the high specific binder c(RGDfV) common contact points to a V b 3 integrin. This difference with the monomer originates from the multivalent presentation of AVTGRGDSY sequence which could bias the binding mode of AVTGRGDSY sequence possibly due to conformational constrains. The specificity of the a V b 3 -RGD recognition is attributed to the sequences flanking the RGDtriad, the auxiliary binding motifs in the ligand, and to a large extent the conformational presentation of the triad.
41) The RGD-triad in our multimers might have a conformational change compared to that in the monomer, and such change possibly improve the a V b 3 specificity. Multivalent effect should be the most possible mechanism for the enhanced affinity, and based on this, a number of studies have used the multimeric structures to improve the in vitro binding affinity of cRGD-containing peptides for a V b 3 integrin. 23, 24, 27, [29] [30] [31] [32] 42) In the present study, we compared the a V b 3 -binding activity of our linear RGD peptides using their radiolabeled forms, which was based on the same dose of radioactivity (60000 cpm/10 ml). Because the RGD-monomer, -dimer and -trimer constructs contain 1, 2 and 3 tyrosines ( 125 I-labeling site) or 1, 2 and 3 RGD sequences, respectively, these factors should be considered when comparing the binding ratios. According to the specific radioactivity, the calculated molar concentrations of 125 I-labeled RGD-monomer, -dimer and -trimer were 2.4ϫ, 2.6ϫ, and 2.9ϫ10 Ϫ11 M respectively. The cooperativity of the binding related to the multivalency of the molecule is visible when comparing the binding ratios of 125 I-labeled RGDs. Indeed, the binding ratios of the multimers, as compared to the monomer, increased more importantly than can be accounted for by the sole additive effect of 2 or 3 RGD units. On the other hand, there was no significant difference in the cell-binding ratios by using different radioactive doses (ranging from 10000 to 60000 cpm) of 125 Ilabeled RGD-monomer, -dimer or -trimer. This may indicate that a certain variation in molar concentrations at the picolevel would not influence the final cell-binding ratio calculated from the percentage of cell-bound radioactivity to the total radioactivity added. It should also be noticed that although there is no doubt that multimerization enhances the affinity, the explanation why is not always obvious to prove. 43) In the present study, there is not much difference between the dimer and trimer. , or the former two, are usually presented together in assay buffer when evaluating the binding affinity of cRGD peptides for a V b 3 integrin. 42, [51] [52] [53] There are also reports that Mn 2ϩ may have a different regulatory effect from Ca 2ϩ and Mg 2ϩ in certain cases. 44, 45, 50) In this study, none of the 3 cations influenced the interaction between RGD-monomer (also -dimer and -trimer) and b 1 integrins. In contrast, we observed Mn 2ϩ -dependent binding of RGD-monomer, -dimer and -trimer to a V b 3 integrin. Arnaout's group reported the crystal structure of integrin a V b 3 in complex with cRGD ligand, showing that 2 Mn 2ϩ cations are present in the structure and are required for the adhesion of RGD. 54 Ilabeled RGD-monomer, -dimer or -trimer to a V b 3 integrin, as compared to the buffer containing Mn 2ϩ alone (data not shown). Hence, we suggest that when evaluating a newly developed RGD-containing product for integrin binding activity, the presence of divalent cations should be documented.
Fluorescence dye Cy5.5-labeling allows the visualization of RGD binding both in vitro and in vivo. Unlike the radio-
